logo-loader
viewVolitionRx

VolitionRx introduces new magnetic particle-based Nu.Q assay format

Volition now expects to see improved clinical performance in the studies it will be carrying out in the coming months

VolitionRx -
The Belgian company has developed easy-to-use blood-based cancer tests which accurately diagnose a range of cancers

VolitionRx Limited (NYSEAMERICAN:VNRX) has developed a new Nu.Q magnetic particle-based assay format, which offers a higher grade of analytical sensitivity. 

As a result of this re-engineering and transition from a microtiter plate format, Volition now expects to see improved clinical performance in the studies it will carry out in the coming months.

The Belgian company has developed easy-to-use blood-based cancer tests, which accurately diagnose a range of cancers. The diagnostic tests are based on the science of nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids to get an indication that a disease is present.

READ: VolitionRx’s Nu.Q cancer-screening blood tests could replace colonoscopies, biopsies

When compared to Volition’s ELISA plate Nu.Q assay format, the company's new magnetic particle-based assay format shows a 10 to 20-fold improvement in analytical sensitivity. It also shrinks the turnaround time of test results to one hour and 20 minutes from six hours.

“I am incredibly proud of the effort the whole team has made in the assay development program over the last two years,” said Dr. Gaetan Michel, CEO of Belgian Volition.

“We now plan to finalize blood plasma sample pre-analytics with these assays and are excited to utilize these automated magnetic chemiluminescent assays in our clinical studies and aim to start reporting data during this quarter, and throughout 2020.”

On top of its other achievements, the magnetic particle-based assay format can also be developed and processed on Random-Access platforms, which permits the use of a wide range of commercial automated platforms.

Volition previously developed synthetic nucleosomes with its partners but has now brought this work in-house with its recent acquisition of Octamer, GMbh, which was announced this month.

Offering another improvement in assay sensitivity as well as extending the usable range of the assays is Volition’s move from a tradition colorimetric endpoint format to a chemiluminescent endpoint.

“The combination of a chemiluminescent endpoint with a magnetic particle-based assay format [has] greatly improved the specificity of Nu.Q assays,” the company said.

In other news, Volition has decreased assay processing time and increased the reliability of assay results by moving onto an FDA-approved automated immunoassay analyzer, which is currently in clinical use across the US and Europe.

Quick facts: VolitionRx

Price: 4.17 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $171.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

4 days, 13 hours ago

2 min read